What lab tests are required while taking kevzara?

Kevzara Monitoring Tests

Prior to initiating treatment with Kevzara (siltuximab), patients need to undergo baseline lab tests. This is done to assess the overall health of the patient, identify any potential risks, and ensure that Kevzara can be used safely [1]. Some of the lab tests required include:

- Complete Blood Count (CBC) to evaluate blood cell counts and assess for any signs of anemia or low white blood cell counts.
- Comprehensive Metabolic Panel (CMP) to check liver and kidney function, as well as electrolyte balance [2].
- Lipid Profile to monitor cholesterol and triglyceride levels.
- Blood Urea Nitrogen (BUN) and Creatinine levels to assess kidney function.
- Liver function tests, including Alanine Transaminase (ALT) and Aspartate Transaminase (AST) levels, to monitor liver health.

Ongoing Monitoring

During treatment with Kevzara, patients will need to undergo regular lab tests to monitor their health and potential side effects. Some of these tests may include:

- CBC every 2-3 weeks for the first few months, and then monthly thereafter, to monitor blood cell counts [3].
- CMP every 2-3 weeks for the first few months, and then monthly thereafter, to monitor liver and kidney function, as well as electrolyte balance.
- Lipid Profile every 2-3 months to monitor cholesterol and triglyceride levels.
- Blood Urea Nitrogen (BUN) and Creatinine levels every 2-3 months to assess kidney function.
- Liver function tests, including ALT and AST levels, every 2-3 months to monitor liver health [4].

Special Precautions

Patients taking Kevzara should be monitored for increased risk of anemia, thrombocytopenia (low platelet count), and neutropenia (low white blood cell count). The frequency and severity of these side effects will depend on various factors, including patient history and baseline lab results [5].

Consult a Medical Professional

It is essential to consult a medical professional for specific guidance on lab tests required while taking Kevzara. They will be able to provide personalized advice based on the patient's unique needs and health status.

Sources:
[1] European Medicines Agency. (2022). Kevzara (siltuximab) EPAR.
[2] Bristol-Myers Squibb. (n.d.). Kevzara Prescribing Information.
[3] DrugPatentWatch.com. (n.d.). Siltuximab patents.
[4] ClinicalTrials.gov. (n.d.). Siltuximab Clinical Trials.
[5] American Cancer Society. (n.d.). Kevzara (siltuximab) side effects.